Table 2.

Effects of 6-week treatments with 75 mg o.d. slow-release indomethacin, 150 mg o.d. eplerenone, or 20 mg o.d. amiloride in 22 patients with genetically proven GS type I who received all three treatments

Parameters	Control Period (Week 6)	Indomethacin (Week 6)	Eplerenone (Week 6)	Amiloride (Week 6)	ANOVA (P Value)
Body weight, kg	69.3±13.1	70.3±13.4a	68.5±12.6b	68.7±13.1b	<0.001
Systolic BP, mmHg	115±9	116±11	115±11	114±10	0.24
Heart rate, beats/min	71.8±10.1	73.5±7.6	75.8±8.0	75.6±9.7	0.07
Plasma potassium, mmol/L	2.8±0.4	3.2±0.4c	3.0±0.5d	3.0±0.5	<0.01
Plasma magnesium, mmol/L	0.54±0.09	0.56±0.07	0.56±0.13	0.58±0.08	0.59
Plasma sodium, mmol/L	140.0±1.6	139.1±1.4	138.6±1.5	138.5±1.6	0.17
Plasma creatinine, µmol/L	61.7±15.1	66.6±17.6e	63.1±15.6	64.8±16.4	0.03
eGFR, ml/min per 1.73 m2	126±28	115±25e	122±24	119±28	0.05
Plasma renin concentration, mU/L	90 (61 to 133)	47 (32 to 69)c	113 (76 to 167)b	112 (76 to 166)b	<0.001
Plasma aldosterone, pg/ml	45 (33 to 62)	42 (30 to 59)	131 (94 to 183)b,c	155 (107 to 124)b,c	<0.001
Urine sodium excretion, mmol/24 h	187 [137–231]	187 [127–207]	186 [143–273]	193 [136–255]	0.50
Urine potassium excretion, mmol/24 h	107 [93–141]	123 [89–134]	104 [90–129]	104 [94–137]	0.95
Urine magnesium excretion, mmol/24 h	2.1 [1.0–3.3]	3.1 [1.4–3.7]	3.0 [1.5–4.6]	1.7 [0.8–3.3]a,d	0.02

Data are mean±SD, geometric mean (95% CI), or median [interquartile range]. ANOVA is P value for the treatment effect in ANOVA for a crossover study. Normal values for plasma renin concentration are 20.8 mU/L (95% CI, 17.7 to 24.4) in men and 16.2 mU/L (95% CI, 13.6 to 19.2) in women. Normal values for plasma aldosterone concentration are 45 pg/ml (95% CI, 39 to 52) in men and 34 pg/ml (95% CI, 28 to 40) in women. mU/L, milli-international units per liter.

^aP<0.05 versus control period.

^bP<0.001 versus indomethacin.

^cP<0.001 versus control period.

^dP<0.05 versus indomethacin.

^eP<0.01 versus control period.